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Background
The aim of the study was to evaluate the impact of preop-
erative radiotherapy on tumor regression by an assess-
ment of Tumor Regression Grade (TRG) in patients with
rectal cancer treated with preoperative short course radio-
therapy and then operated on after a medium interval of
30 days.
Materials and methods
From July 2002 to September 2008 31 patients were
enrolled: 16 women aged between 65 and 77 (average age
71 years) and 15 males aged between 69 and 85 (average
age 77 years) with rectal cancer.
All patients underwent endorectal ultrasound and MRI
pre-and post-radiotherapy treatment. Included patients
had rectal cancer T2N0 within 5 cm from the anal margin
or patients with cancer of the medium rectum T3 N0 or
patients with cancer T3N1/T4 deserving preoperative
treatment but not fit for a combined chemo-radiotherapy
due to co-morbidities.
All patients underwent a short cycle of radiotherapy 5 × 5
Gy (25 fractions) and then were operated after restaging.
Results
Postradiotherapy complications occurred only in 6
patients (19%): local pain (1), tenesmus (1), erythema
(2), actinic proctite (2). The medium time between radio-
therapy and surgery was almost 30 days. The post-opera-
tive mortality was 6% (2 patients): in both cases the exitus
was due to heart failure. Pathological examination
showed: 1 T3N2G2; 2 T3N1G2; 4 T3N0G2; 3 T2N2G2; 6
T2N0G2; 1 T1N1G2; 10 T1N0G2; 2 T2N1G2; 1 T2N1G1;
1 T0N0G2. Downstaging of the primary tumor occurred
in 79.3% of cases. Average examinated lymph nodes
number was 42 (range 18–66). TRG analysis showed: 1
TRG 5 (3%); 12 TRG 4 (39%); 9 TRG 3 29%; 8 TRG 2
(26%); 1 TRG 1 (3%).
The 10 N+ patients underwent adjuvant chemotherapy.
At a median follow-up of 38 months (range 2–74) there
were: 2 local recurrences (1 treated with abdominalperi-
neal resection), 1 lung metastases, 1 liver metastases, 1
brain metastases. Three of them are undergoing second-
line chemotherapy. Four patients have died so far (2 post-
operatively, 2 spread disease).
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Short radiotherapy followed by a long interval (30 days)
and surgery produces a high rate of downstaging but has
a low impact on tumor regression.Page 2 of 2
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